Trebananib Completed Phase 1 Trials for Tumors Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT00102830Study Evaluating AMG 386 in Adult Patients With Advanced Solid Tumors